Molbio Diagnostics Limited · NSE:MOLBIO
Molbio Diagnostics — Q1 FY27 Earnings Presentation
24 slides from Molbio Diagnostics's earnings presentation, September 2026
Slide 1: Innovation Led Diagnostic Products Company
Innovation Led Diagnostic Products Company Investor Presentation Sept’2026
Slide 2: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which has been prepared by Molbio Diagnostics Ltd . (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 3: Management Commentary
Management Commentary “ "FY 27 is a milestone year for Molbio, marking our transition to a listed company . I would like to thank our shareholders, employees, customers and partners for the trust they have placed in Molbio through our recent listing, and we remain committed to delivering on that tru
Slide 4: Company & Business Overview
Company & Business Overview
Slide 5: Founders' Journey
Founders’ Journey 1990 - 2004 2005 - 2018 Sriram Natrajan, co - founded, Tulip Diagnostics Private Bigtec shifts its focus Joint Venture between Sriram Natarajan Limited which later towards chip - based Molbio and Bigtec exited Tulip became one of the PCR (1) research Innovations Private Diagnostics
Slide 6: Journey Post Commercial Launch of Truenat Platform
Journey Post Commercial Launch of Truenat Platform 2019 - 2022 2023 onwards • Prognosys 5 received EU MDR certification for the PRORAD radiology systems • Truenat HR - HPV Plus met IARC • Strategic validation criteria in a multicentre study investment in Investment by Investment by OptraSCAN , a • C
Slide 7: Molbio At A Glance
Molbio At A Glance Innovation - led diagnostics company delivering accessible, accurate and affordable molecular testing Broad & Growing Test Menu Global Scale & Adoption Recurring Business Model Proprietary Technology 12,500+ 73.98% 43 30 Truenat ® Devices Installed Product Revenue from Truenat ® A
Slide 8: R&D Engine: Proven Innovation, Sustained Investment
R&D Engine: Proven Innovation, Sustained Investment Deep scientific capability translated into scalable products, protected IP and future growth Proven Innovation Capability Investing More To Drive Future Growth Annual R&D investment (₹ Cr) From scientific insight to scalable impact Multidisciplinar
Slide 9: Global Healthcare Burden - The Problem Statement
Global Healthcare Burden - The Problem Statement A significant diagnostic access gap continues to delay timely diagnosis, treatment and better health outcomes Diagnostics Are Critical, Yet Underpenetrated High Disease Burden Continues To Impact Global Health H ealthcare decisions depend 70% on diagn
Slide 10: From Centralized To Decentralized Point Of Care Diagnostics
From Centralized To Decentralized Point Of Care Diagnostics Emerging Need Decentralized / Point-of-care Diagnostics Earlier Greater Test at or near Minimal Faster clinical reach & the patient infrastructure Results decision impact Traditional Model Centralized Laboratory Diagnostics Sample Sample Lo
Slide 11: The Truenat Platform - An Integrated Workflow
The Truenat Platform - An Integrated Workflow Device Key Platform Attributes UnoDx Portable Fully Automatic (1 test) Lightweight and Minimal hands - on easy to transport time and easy to use Duo Battery Operated Point - of - care Ready (2 tests) Works in areas with Designed for use at or unreliable
Slide 12: Consumables - Powering A Recurring Revenue Engine
Consumables - Powering A Recurring Revenue Engine Disease-specific Consumables What Constitutes The Consumable • Truenat® test kits are disease-specific, ready-to- Truenat Test Kit use and single-use • Micro-PCR chips contain pre-loaded PCR reagents for real-time PCR testing + + • Designed for use e
Slide 13: Presence across 30 Diseases in the Fast-Growing POCT Market
Molbio has Presence across 30 Diseases in the Fast - Growing POCT Market for Infectious Diseases Infectious Disease Testing Represents …With TB Tests Being the Leading Contributor Significant Testing Market Across Diseases Significant Segment of Global POC(4) Market… Global POC (4) Diagnostic Market
Slide 14: State of Art Manufacturing Facilities
State of Art Manufacturing Facilities Scaled, Multi - location Manufacturing Meaningful Installed Capacity With Automation - enabled Manufacturing Footprint Headroom 6 Manufacturing Facilities | 4 Locations Automation For Precision & TRUENAT® TEST TRUENAT® Consistency KITS DEVICES GOA Manufacturing
Slide 15: Quality Certifications
Quality Certifications Integrated Quality Assurance & Quality International Quality Management Regulatory & Product - level Validation Control Systems 221 QA / QC ISO 13485:2016 MDSAP PROFESSIONALS ISO MDSAP • Dedicated QA - QC division at each manufacturing facility • Rigorous testing of raw materi
Slide 16: Prognosys: Enhancing Universal Access Portfolio with Radiology Imaging Devices
Prognosys : Step Towards Enhancing Our Universal Access Portfolio with Radiology Imaging Devices Prognosys Acquisition Unlocking Multiple Levers to Enhance Our Digital Radiology Capabilities (2) US FDA approved range of digital imaging solutions with a strong pipeline of ultra portable devices acro
Slide 17: AI-powered, Digital Pathology Solutions Enabling Remote Consultations
AI - powered, Digital Pathology Solutions Enabling Remote Consultations and Collaborations Investment in US based Company Furthering Global Reach and Diversifying Offerings Whole Slide Scanner Comprehensive Digital pathology Solutions Provides digital pathology solutions, offering a range of digital
Slide 18: Growth Strategy
Growth Strategy Expand Our Geographical Presence across Develop New POC(1) Platforms for Other the Globe Communicable and Non - Communicable Diseases Focus on enhancing exports, particularly to regions Leverage R&D Capabilities to Develop New POC(1) Platforms Using Advanced where we have presence, s
Slide 19: Financials Performance - Quarter
Financials Performance - Quarter
Slide 20: Q1 FY27 Performance Highlight (Y-O-Y)
Q1 FY27 Performance Highlight (Y - O- Y) Total Income* EBITDA * EBITDA Margin PAT PAT Margin ₹411.5 Cr ₹103.7 Cr 25.2% ₹52.7 Cr 12.8% Truenat ® Devices Sold (Units) Truenat ® Test Kits Sold (Mn Units) 6.2 1,158 5.4 213 164 0.8 Q1 FY26 Q4FY26 Q1 FY27 Q1 FY26 Q4FY26 Q1 FY27 *Total Income & EBITD
Slide 21: Profit & Loss Highlights – Quarterly
Profit & Loss Highlights – Quarterly Total Income* (₹ Cr.) EBITDA * (₹ Cr) & Margin % Net Profit (₹ Cr) & Margin % (14.4% ) 28.9% 25.2% (23.8% ) 16.9% 12.8% 565.4 163.5 95.8 411.5 103.7 52.7 100.5 - 14.5 - 23.9 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 • Q1 FY27 Total
Slide 22: Profit & Loss Statement – Quarterly
Profit & Loss Statement – Quarterly Particulars (₹ Cr) Q1 FY27 Q1 FY26 Q4 FY26 Revenue from Operations 408.4 99.7 560.6 Other income 3.1 0.8 4.8 Total income 411.5 100.5 565.4 COGS 149.7 35.2 235.4 Employee Benefit Expenses 45.9 28.2 45.9 Other Expenses 112.2 51.6 120.6 EBITDA 103.7 (14.5) 163.5 EBI
Slide 23: Value Proposition
Value Proposition Proprietary POC • Truenat ® brings real - time PCR capabilities closer to the patient Molecular Diagnostics • Portable, battery - operated platform designed for decentralised testing Platform • Enables molecular diagnostics in resource constrained and remote settings • Delivers mol
Slide 24: Thank You
THANK YOU For any investor queries, please contact Molbio Diagnostics Limited Adfactors PR - Investor Relations Indraneil Borkakoty - President – Corporate Strategy, Smit Shah / Anand Venugopal Mergers & Acquisitions and Investor Relations +91 98707 89596 / +91 70218 52071 indraneil.borkakoty@molbio